KCK

KCK Group is a prominent single-family office based in New York, with additional offices in San Francisco and London, underscoring its global reach. As a family investment fund, KCK distinguishes itself through a flexible and long-term investment horizon, unconstrained by typical fund cycles. The firm deploys capital across a diverse portfolio of industries, including healthcare, technology, industrials, and real estate. This broad mandate allows KCK to engage with companies at various stages of their lifecycle, from early-stage ventures to more mature growth equity opportunities, reflecting a versatile investment strategy.

In the medical technologies sector, a key area highlighted by the user, KCK has demonstrated a strong track record of backing innovative companies. Their investment approach often involves providing significant capital to support commercialization and expansion. For instance, KCK Group led a $50 million Series E funding round for CardioFocus, a medical device company, in 2019, showcasing their capacity to lead substantial growth-stage investments. They also participated in a $66 million Series F round for Pulmonx, a company focused on interventional pulmonology, in 2018, further illustrating their commitment to high-growth healthcare innovators.

KCK's investment philosophy emphasizes strategic partnerships and a patient capital approach, often taking a significant stake in portfolio companies. While their investment sizes can vary widely due to their multi-stage and multi-sector mandate, typical first checks for growth-stage opportunities often fall within the range of $5 million to $25 million. However, given their stated interest in early-stage ventures and strategic smaller deals, their minimum check size could be as low as $2 million, particularly for highly promising, nascent technologies or follow-on rounds. KCK's value proposition extends beyond capital, offering strategic guidance and leveraging their extensive network to support the growth and success of their portfolio companies.